Nations Financial Group Inc. IA ADV Has $50,000 Stock Position in Anixa Biosciences, Inc. (NASDAQ:ANIX)

Nations Financial Group Inc. IA ADV grew its holdings in shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) by 50.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,500 shares of the company’s stock after purchasing an additional 7,500 shares during the quarter. Nations Financial Group Inc. IA ADV owned about 0.07% of Anixa Biosciences worth $50,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Virtu Financial LLC raised its holdings in Anixa Biosciences by 47.2% during the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after buying an additional 5,183 shares in the last quarter. Staley Capital Advisers Inc. acquired a new position in shares of Anixa Biosciences during the 1st quarter valued at about $31,000. Finally, Simplicity Wealth LLC bought a new position in shares of Anixa Biosciences in the 1st quarter valued at approximately $44,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ANIX shares. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research report on Wednesday, July 24th. EF Hutton Acquisition Co. I upgraded shares of Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Anixa Biosciences Price Performance

ANIX stock opened at $3.34 on Friday. The stock has a market capitalization of $106.90 million, a price-to-earnings ratio of -9.03 and a beta of 0.89. The company has a 50-day moving average of $2.91 and a two-hundred day moving average of $3.04. Anixa Biosciences, Inc. has a 52-week low of $2.14 and a 52-week high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Tuesday, June 4th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. Equities analysts expect that Anixa Biosciences, Inc. will post -0.43 EPS for the current fiscal year.

Insider Transactions at Anixa Biosciences

In related news, Director Lewis H. Titterton, Jr. acquired 10,738 shares of the stock in a transaction dated Friday, June 7th. The shares were acquired at an average price of $2.52 per share, for a total transaction of $27,059.76. Following the completion of the purchase, the director now owns 848,775 shares in the company, valued at approximately $2,138,913. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Lewis H. Titterton, Jr. purchased 21,646 shares of the stock in a transaction that occurred on Tuesday, July 30th. The shares were purchased at an average cost of $3.06 per share, for a total transaction of $66,236.76. Following the completion of the purchase, the director now directly owns 890,754 shares of the company’s stock, valued at approximately $2,725,707.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Lewis H. Titterton, Jr. purchased 10,738 shares of the business’s stock in a transaction on Friday, June 7th. The stock was purchased at an average cost of $2.52 per share, with a total value of $27,059.76. Following the acquisition, the director now owns 848,775 shares in the company, valued at $2,138,913. The disclosure for this purchase can be found here. Insiders acquired a total of 69,369 shares of company stock worth $185,948 over the last three months. 22.60% of the stock is currently owned by insiders.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.